MedTrace Logo

Concentrations of Formoterol in Blood and Urine

NCT00914654 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-06-05

No results posted yet for this study

Summary

The purpose of the study is to assess the blood and urine concentrations of inhaled formoterol.

Conditions

Interventions

DRUG

inhaled formoterol

Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.

Sponsors & Collaborators

  • Hormone Laboratory, Aker University Hospital, Oslo, Norway

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Jimmi Elers, MD · Bispebjerg Hospital, Respiratory Research Unit

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914654 on ClinicalTrials.gov